A systematic review of potential screening biomarkers for active TB disease

James H. Wykowski a, *, Chris Phillips b, Thao Ngo b, Paul K. Drain a, b, c

a Department of Medicine, 925 9th Ave Seattle, WA 98104, University of Washington, Seattle, USA
b Department of Global Health, 925 9th Ave Seattle, WA 98104, University of Washington, Seattle, USA
c Department of Epidemiology, 925 9th Ave Seattle, WA 98104, University of Washington, Seattle, USA

ARTICLE INFO

Keywords: Tuberculosis Screening Systematic review

ABSTRACT

Introduction: The standard TB Four Symptom Screen does not meet the World Health Organization (WHO) ideal screening criteria for having greater than 90% sensitivity to identify active TB disease, regardless of HIV status. To identify novel screening biomarkers for active TB, we performed a systematic review of any cohort or case-control study reporting associations between screening biomarkers and active TB disease.

Methods: We searched PubMed and Embase for articles published before October 10, 2021. We included studies from high or medium tuberculosis burden countries. We excluded articles focusing on C-reactive protein and lipoarabinomannan. For all included biomarkers, we calculated sensitivity, specificity and 95% confidence intervals, and assessed study quality using a tool adapted from the QUADAS-2 risk of bias.

Results: From 8,062 abstracts screened, we included 79 articles. The articles described 302 unique biomarkers, including host antibodies, host proteins, TB antigens, microRNAs, whole blood gene PCRs, and combinations of biomarkers. Of these, 23 biomarkers had sensitivity greater than 90% and specificity greater than 70%, meeting WHO criteria for an ideal screening test. Among the eleven biomarkers described in people living with HIV, only one had a sensitivity greater than 90% and specificity greater than 70% for active TB.

Conclusion: Further evaluation of biomarkers of active TB should be pursued to accelerate identification of TB disease.

1. Introduction

Tuberculosis (TB) has surpassed HIV globally as the leading infectious cause of death, with approximately 1.51 million deaths worldwide in 2020 [1]. One major barrier to eradicating TB is that the standard screening tools for active TB have limited sensitivity, particularly among people living with HIV (PLHIV). Currently, the World Health Organization (WHO) recommends screening using the Four Symptom Screen (fevers, cough, night sweats, weight loss) either in isolation or in combination with chest radiographs and other screening tests [2]. However, Four Symptom Screen has an estimated sensitivity of 60–80% depending on the population studied [3]. The sensitivity of symptom-based TB screening also varies based on HIV status, from as low as 51% in people taking ART, to 89% in ART-naive individuals [2,4]. The WHO has called for increasing support for biomarker research and development in the END TB strategy [5].

TB screening tools identify people with high likelihood of active TB. These stand in contrast to diagnostic tools, which confirm active TB disease. The WHO have described an ideal TB screening tool as having greater than 90% sensitivity and 70% specificity regardless of HIV status [2]. Existing reviews on TB screening have described the test characteristics of symptom screening algorithms [4], C-reactive protein (CRP) [6], urine lipoarabinomannan (LAM) [7], and sputum Xpert MTB/RIF and Xpert Ultra [8]. Urine LAM proved to have very poor sensitivity [7,9]. CRP has also been proposed as a screening tool, however a meta-analysis demonstrated that while CRP may be more sensitive than symptom screening [6], the sensitivity is still lower than the 90% threshold set by the WHO for a TB screening test [2]. Previous systematic reviews of other TB biomarkers have focused on TB diagnostics in cohorts of patients presenting with TB symptoms rather than true alternatives to TB symptom screening [10,11].

Since improved screening tools will be imperative to ending the TB pandemic, we sought to characterize the existing literature regarding screening biomarkers for active tuberculosis to further guide research and development of novel TB screening tools.

* Corresponding author.
E-mail address: jwykow@uw.edu (J.H. Wykowski).

https://doi.org/10.1016/j.jctube.2021.100284

Available online 5 November 2021
2405-5794/© 2021 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Methods

2.1. Search strategy and study selection

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [12], we searched PubMed and Embase for articles published since database inception through October 10, 2021. Keywords for our search included tuberculosis, screening, and a list of countries with high or medium burden of tuberculosis according to the WHO [13]. The full search protocol is available in the included online supplement. We registered our review with the PROSPERO database, with registration number CRD420211499957. In part due to delays in processing due the COVID-19 pandemic, our registration was not complete until after the initial article search.

We extracted results from each database search to Covidence.org [14]. We removed duplicate search results, and two authors (JW and CP) independently reviewed titles and abstracts, discussing disagreements prior to making a final decision. The same authors then conducted full-text review, and again discussed disagreements prior to making final decisions. Excluded full-text articles were categorized based on reason for exclusion. The authors performed data extraction on the included articles using a standardized form.

Using a pre-specified format adapted from the QUADAS-2 risk of bias tool [15], the authors independently assessed risk of bias and study applicability and again reviewed disagreements prior to making a final decision.

2.2. Eligibility criteria

We included cross-sectional, retrospective, and prospective cohort studies, randomized controlled trials, and case-control studies. We included case-control studies that described biomarker performance among TB cases and controls. We excluded qualitative studies, systematic reviews, and non-peer reviewed abstracts. For non-case control studies, we excluded studies where the population of interest included only tuberculosis suspects, or participants who had already screened positive using the Four Symptom Screen. Using WHO definitions [13] we included any paper reporting data from a high or medium TB burden country.

Our primary exposures of interest were screening biomarkers for tuberculosis. We included any study of a population being screened for active TB disease that reported a biomarker, sensitivity and specificity for active TB disease, or reported raw numbers allowing for the calculation of sensitivity, specificity and 95% confidence intervals. We excluded studies that only included a cohort suspected to have active TB disease based on symptoms or other prior screening. Given the existing published literature, we excluded urine and serum lipoarabinomannan (LAM) and C-reactive protein (CRP), unless used as part of a composite screening tool utilizing multiple biomarkers (e.g. LAM and hemoglobin) [6,9]. We also excluded papers describing the use of sputum Xpert TB/RIF (Cepheid) or sputum Xpert Ultra as screening tests. We excluded papers that used immunobeads typically used to screen for latent tuberculosis, including interferon gamma release assays (IGRA) or tuberculin skin tests (TST).

Our primary outcome of interest was active TB disease. We defined active tuberculosis as participants who had infections confirmed by sputum culture, smear, GeneXpert, clinical diagnosis, or response to anti-tuberculosis therapy. We recorded the method of tuberculosis diagnosis when reported. When papers reported multiple methods of tuberculosis diagnosis, we pooled outcomes. We recorded the total number of biomarkers tested, and we extracted any biomarker with a sensitivity greater than 75%. We stratified biomarkers by those meeting WHO criteria for a TB screening test (sensitivity greater than 90%, specificity greater than 70%), and those not meeting criteria.

2.3. Statistical analysis

When not reported, we calculated sensitivity, specificity, and 95% confidence intervals for each reported biomarker. We planned to conduct pooled meta-analysis for individual biomarkers, however, there was not sufficient data to do so.

We assessed study quality and applicability concerns using a pre-specified tool adapted from the QUADAS-2 risk of bias tool. The full evaluation tool is described in Online Supplement 2. In evaluating study quality, we assigned sputum culture and sputum GeneXpert as being associated with a low risk of bias, and any other method of TB diagnosis as associated with a high risk of bias.

3. Results

3.1. Search results

Our search returned 8444 articles for review. After removing duplicates, two authors (JW and CP) screened the 8062 remaining abstracts (Fig. 1). 7158 titles were excluded at the title/abstract level, leaving 481 articles for full-text review. We included 79 studies for full data extraction and review [16-94].

3.2. Characteristics of the included studies

The full characteristics of the 79 included studies are described in Online Supplement 3. Ten of the included studies were cohort studies; the remaining 69 studies were case-control studies. The sample size ranged from 129 to 3123 participants among cohort studies, and from 40 to 1813 participants among the case-control studies. 33 studies (45.2%) were located in China. Other countries with multiple included studies were India (12), South Africa (9), Brazil (6), and Pakistan (4). Two studies each were located in Ethiopia, Peru, Tunisia, Uganda, and Vietnam. One study each was located in Turkey, Guinea-Bissau, Singapore, Thailand, Gambia, and Mozambique. Four studies included data from multiple countries.

3.2.1. Outcomes

The ten included cohort studies described eleven unique biomarkers. The 69 included case-control studies described 291 unique biomarkers. The most common type of biomarker reported was host antibody, or combination of multiple host antibodies. This included both existing TB antibody test kits and novel antibody tests. Other types of commonly reported biomarkers included host proteins, TB proteins, and microRNAs.

Of the total 302 described biomarkers, 23 met the WHO criteria of sensitivity greater than 90% and specificity greater than 70% (Table 1). This included nine antibody tests (Fig. 2A and fourteen non-antibody tests (Fig. 2B. Sixteen of these tests included a single biomarker, while seven included a combination of biomarkers. Only one of the ten included cohort studies described a biomarker meeting WHO criteria, which was a single TB gene PCR [25].

Another 78 biomarkers did not meet WHO criteria, but had a reported sensitivity of greater than 75%. Their sensitivities, specificities, and 95% confidence intervals are described in Online Supplement 5. These included 35 antibody tests, five microRNAs, four small RNAs, five Gene PCR tests, four TB proteins, ten host lipids, eight host proteins, two synthetic peptides, two host cells, and one exhaled nitric oxygen breath test.

3.2.2. People living with HIV

Among both cohort and case-control studies, twelve studies included only PLWH, or included subgroup analyses of PLWH, describing eleven unique biomarkers. These included anemia (serum hemoglobin < 12 mg/dl) [31,76], absolute neutrophil count [30], serum neopterin [21], serum anti-mycolic acid IgG antibody [51], a combination of anti-6, 27,
30, and 38 kDa Tb antigen IgG antibodies [52], serum Mycot dot assay [28], three serum gene PCR tests [87,92,95], and a combinations of three TB antigens [79].

Of these, three biomarkers met the WHO criteria, including the RISK6 genomic score, TB Gene IS 6110 PCR, and a combination of five TB antigens including 6, 27, 30, 38 and 64 kDa antigens (Table 2). An additional four biomarkers had sensitivity greater than 90% but low specificity. These included combination of three antigens, Rv0934-P38, Ag85A, and Rv2031-HSPX [79], serum neopterin [21], anti-mycolic acid IgG [51], Xpert-MTB-HR-Prototype [92].

3.3. Assessment of risk of bias and applicability

A summary of the risk of bias and applicability concerns is described in Fig. 3, with full results for each study available in Online Supplement 4. Risk of bias generally high due to the large proportion of case-control studies included. Additionally, few studies described blinding procedures for those interpreting index tests, and few studies specified the time between gold-standard testing and obtaining samples for the index test. In 38 studies, TB was diagnosed by sputum culture, GeneXpert, or biopsy (in the case of extra-pulmonary disease. Other methods used to diagnose TB in the other 41 studies included sputum smear, chest radiograph, clinical symptoms, and response to anti-TB therapy.

4. Discussion

In this review, we summarized the extensive literature describing biomarkers for TB screening. We identified 23 biomarkers that met the WHO criteria of a sensitivity greater than 90% and specificity greater than 70%. These biomarkers may be promising candidates towards developing a novel screening tool that can outperform standard TB symptom screening. However, many of the biomarkers are described in early phase studies with low quality evidence; more data are needed to definitively evaluate these biomarkers as effective screening tools.

Previous literature describing novel TB screening biomarkers has focused on CRP, LAM, and sputum Xpert MTB/RIF and Xpert Ultra [6,8–9]. These tests have good potential as screening tools as they are inexpensive and easily implemented at the point of care, making them an easy replacement or complement to community-based symptom screening. Unfortunately, urine LAM has proven to have inadequate sensitivity to be used as a screening tool [7]. CRP has relatively low specificity but may still have a role to play in community-based screening [6]. Both sputum Xpert tests have high specificity, but low sensitivity when used as primary screening test rather than their typical use as a diagnostic test [96]. Their reliance on participants’ capacity to produce a sputum sample at the time of testing likely limits their sensitivity as a screening test. This review expands the existing conversation on TB biomarkers by identifying novel screening tools. While we were unable to identify a single biomarker with enough evidence to recommend implementation currently, there are a number of promising targets, including host and pathogen proteins as well as genetic tests.

Identifying screening tools for PLWH remains a WHO priority given the high prevalence and mortality of tuberculosis among PLWH. Unfortunately, the paucity of studies in Table 2 demonstrates that relatively few biomarkers with promising test characteristics exist for PLWH. However, many of the gene PCR tests included in this review show promise as further screening tests, particularly among PLWH. When tested in a cohort containing only PLWH, the RISK6 genomic score had a sensitivity of 90.50% and specificity of 72.5% [95], while another study found TB Gene IS 6110 PCR had a sensitivity of 96.2% in a cohort with an HIV prevalence of 87.6% [25]. Another study of PLWH described a novel gene signature with sensitivity greater than 90% and specificity greater than 70%, but did not report exact sensitivity and specificity and thus was not included in this review [97]. Additionally, one study
strategies. We also did not define standard time to tuberculosis diagnosis cations highlight that some screening tests may have value in this setting into a point-of-care PCR test. [96], which could serve as a model for how to turn novel gene signatures eXpert MTB/RIF (Cephid) testing is feasible as a mobile screening tool -ation in TB genomics has the potential to limit the external validity of -described a 3-gene score with sensitivity of 90.9% in a cohort with low tuberculosis disease, defining active tuberculosis is difficult, and may limits their sensitivity. Additionally, the definition of screening for active tuberculosis in our review excludes incipient TB. Recent publications highlight that some screening tests may have value in this setting [77], and may be an important tool in improving overall screening strategies. We also did not define standard time to tuberculosis diagnosis for confirmed cases, but instead used each individual studies’ case definition, resulting in significant heterogeneity. Finally, because the WHO Target Product Profile for a screening test is defined by sensitivity and specificity [5], we only reported these two metrics for included biomarkers. Positive and negative predictive value may also be valuable metrics by which to consider screening tests, particularly in high-burden settings. For example, the RISK11 gene signature test did not meet WHO criteria based on sensitivity (86.5% vs. 90%), but had a negative pre-
Fig. 2. Sensitivity, specificity and 95% confidence intervals for tests meeting WHO Criteria.
applied against the WHO criteria for a screening test, these studies may have been designed to evaluate the potential of biomarkers as diagnostic tests. Of the few included cohort studies, only one described a biomarker that met WHO criteria. Many of the biomarkers showing promise in case control studies may not hold up to the scrutiny of more rigorous cohort studies and randomized controlled trials. Additionally, many of the included studies did not use gold-standard methods for diagnosing TB, instead using methods with poor sensitivity (sputum smear), poor specificity (clinical presentation), or both. Few studies reported study flow procedures like blinding and timing of sample acquisition, limiting our ability to fully assess their quality.

We chose to only include studies located in countries with a high or medium prevalence of tuberculosis in order to capture settings that would most benefit from improved TB screening tools. This decision limits the applicability of our findings to low-burden countries. A majority of the included studies were located in China (31 of 72) or India (12 of 72). In contrast, only 13 of 72 studies were located in sub-Saharan Africa, seven of which were in South Africa. Of the 23 biomarkers identified meeting WHO criteria, only 3 were described in sub-Saharan Africa, all in South Africa. One of the 23 biomarkers was described in Thailand. Sub-Saharan Africa is more strongly represented among the studies describing PLWH, consistent with the global burden of TB/HIV co-infection. The over-representation of Chinese and Indian studies in our sample suggests our results may not be applicable to sub-Saharan Africa, where largest burden of tuberculosis currently exists. Prior to implementation, biomarkers would need to be validated in sub-Saharan Africa.

| Author | Biomarker | Sensitivity (95% CI) | Specificity (95% CI) | People with TB (Total Participants) | Biomarker Type |
|--------|-----------|----------------------|----------------------|--------------------------------------|----------------|
| Tiwari 2013 [52] | Combination of 5 TB antigens: 6, 27, 30, 38 and 64 kDa | 99.2% (95.2–100%) | 98.3% (89.9–99.9%) | 130 (190) | Combination of TB antigens |
| Penn-Nicholson 2020 [77] | RISK6 Genomic Score | 90.5% (76.0–97.0%) | 72.5% (56.3–84.6%) | 40 (82) | TB Gene PCR |
| Hira 2010 [25] | TB Gene IS 6110 PCR | 95.83% (84.6–99.3%) | 84.61% (73.1–92.0%) | 48 (113) | TB Gene PCR |

Fig. 3. Risk of Bias and Applicability Concerns for all included studies.
African, both to account for regional variations in TB epidemiology and genomics, but also for a larger burden of TB-HIV co-infection. While effective screening remains a key part of eradicating TB, current screening tools are inadequately specific, and do not meet the WHO threshold of 90% sensitivity. We described the existing literature on TB screening tools and identified many biomarkers that are candidates for further study. In particular, host response genetic PCR tests may be good further study. In particular, host response genetic PCR tests may be good

Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements
We would like to thank Sarah Safranek, UW Librarian, for assistance with drafting the search protocol. We would also like to thank the members of the Drain TB/HIV/COVID-19 Research Lab for their contributions and feedback.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jctube.2021.100284.

References
[1] Global tuberculosis report 202Geneva; 2021.
[2] WHO. Systematic screening for active tuberculosis. 2013: 1-146.
[3] van’t Hoog AH, Langendam M, Mitchell E, Cobelens FG, Sinclair D, Leflang MMG, et al. Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status. Cochrane Database Syst Rev 2014;2014:CD010895.
[4] Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Comparison of soluble protein assays for the early detection of tuberculosis. Int J Tuberc Lung Dis 2017;21:1013-9.
[5] Shah M, Hanrahan C, Crockett J, Dendukuri N, Shishehbor M, Luthra S, et al. Flow cytometry and plasma flow cytometry for detecting active tuberculosis in HIV-positive patients. Review 2016.
[6] Shapira AE, Ross JMM, Yao M, Schiller I, Kohli M, Dendukuri N, et al. Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms. Cochrane database Syst Rev England 2021;2021(3). https://doi.org/10.1002/14651858.CD013994.pub2.
[7] Correa-Neves M, Froebig K, Karthaus L, Viegas S, Vaz P, Ramanal L, et al. biomarkers for tuberculosis: the case for lipolysaccharin. J Exp Open Res 2019;5(1):00115-18. https://doi.org/10.18133/jexpopenres.00115-18.
[8] MacLean E, Broger T, Verkikas S, Fernandez-Carballo BI, Poi M, Denkinger CM. A systematic review of biomarkers to detect active tuberculosis. Nat Microbiol [Internet] Springer, US 2019;4(5):748-58. https://doi.org/10.1038/s41564-019-0380-2.
[9] Steinwart KR, Flores LL, Dendukuri N, Schiller J, Lai S, Ramsay A, Hopewell PG, Poi M. Common Serological Tests for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis: An Updated Systematic Review and Meta-Analysis. PLoS Med. [Internet] Public Library of Science; 2011; 8:e1001062Available from: 10.1371/journal.pmed.1001062.
[10] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med United States 2009;6(6):e1000097.
[11] WHO. Use of high burden country lists for TB by WHO in the post-2015 era. WHO Press 2015: 19.
[12] Veritas Health Innovation. Cochrane Systematic Review Software [Internet]. Tyrone, United Kingdom 2018. Available from: www.cochranelibrary.com.
[13] Whiting PF, Rutjes AW, Reitsma JB, Kleijnen J, Deeks JJ, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2015: 19.
[14] PR A, Latha G, Valluri V, Mukhopadhyay S. Mycobacterium tuberculosis PPE protein Rv0256c induces strong B cell response in tuberculosis patients. Infect. Genet. Evol. [Internet] 2015; 22: 244-249Available from: http://www.embase. com/search/results?subaction=from-export&accid=1600364590 NS =. Available from: NS -.
[15] Ali N, Hussen A, Schiller I, Sinanc A, Salmenkangas P, Sengupta S, et al. There is a value of mantoux test and erythrocyte sedimentation rate in preemployment screening of health care workers for tuberculosis in a high prevalence country? Int J Tuberc Lung Dis 2002;6: 1012-6. Available from: NS -.
[16] Cao S, Chen Y, Sun Y, Liu Y, Zheng S, Zhang Z, et al. Screening of serum biomarkers for distinguishing between latent and active tuberculosis using proteome microarray. Biomed Environ Sci [Internet] 2018;31:515A-26A. Available from: NS -.
[17] Chen T, Liu J, Wang W, Fleming J, Chen L, Wang Y, et al. Cytokine and Antibody Based Diagnostic Algorithms for Sputum Culture-Positive Pulmonary Tuberculosis. PLoS One [Internet] 2015;10:e0144705. Available from: NS -.
[18] Chen Z, Wei L, Shi L, Mi J, Jiang T, Chen J, et al. Screening and identification of IncA/B as potential biomarkers for pulmonary tuberculosis. Sci Rep [Internet] 2017;7:16751. Available from: NS -.
[19] Ciccacci F, Floridiana M, Bernardini R, Sifumlo Z, Mangushe R, Andrettini M, et al. Plasma levels of CRP, neopterin and IP-10 in HIV-infected individuals with and without pulmonary tuberculosis. Int J Clin Tuberc Other Mycobact Dis [Internet] 2019;16:16. Available from: http://www.embase.com/search/results?subaction=from-export&accid=12002909565 NS -.
[20] Conde M, Saffy S, Lapa E, Silva J, Kritski A, Dornamahiginnoblon A (IgA) and IgG immune responses against P-90 antigen for diagnosis of pulmonary tuberculosis and screening for Mycobacterium tuberculosis infection. Clin Diagn Lab Immunol [Internet] 2004;11:94-7. Available from: NS -.
[21] Gupta A, Srinivasta S, Singh A, Singh S. Development of rapid immuno-diagnostic test for the early detection of tuberculosis. Int J mycobacteriol [Internet] 2016;5 (Suppl 1):511-5. Available from: NS -.
[22] Gupta S, Shende N, Baseerje S, Kumar S, Reddy M, Hariniab N. Analysis of SEVA TB ES-31 antigen specific immunoglobulins IgM, IgA and IgG in sera of sputum and culture positive pulmonary tuberculosis. Indian J Clin Biochem [Internet] 2002;17:5-8. Available from: NS -.
[23] Hira R, Sarangdhar V, Hira S, DuPont H. Peripheral blood PCR for detection of Mycobacterium tuberculosis in patients with HIV/AIDS in Mumbai, India. Internet J. Microbiol. [Internet] 2010; 9Available from: http://www.embase.com/search/results?subaction=from-export&accid=135995360 NS -.
[24] Jiang T, Shi L, Wei L, Li XJ, Yang S, Wang C, et al. Serum amyloid protein A, and C4b-binding protein J chain as new potential biomarkers for pulmonary tuberculosis. PLoS One [Internet] 2017;12:e0173304. Available from: NS -.
[25] Jiao W, Wang M-S, Yang X-G, Wang X-F. Evaluation of ALS assay of TB-SA for diagnosis of pulmonary tuberculosis. J Immunol Immunopath [Internet] 2015; 36(2):119-27. Available from: NS -.
[26] Antunes A, Nina J, David S. Serological screening for tuberculosis in the community: an evaluation of the Myocod procedure in an African population with high HIV-2 prevalence (Republic of Guinea-Bissau). Res Microbiol [Internet] 2002; 153(5):301-5. Available from: NS -.
[27] Kashyap R, Nayak A, Gaharwar H, Bsslar S, Huxain A, Shekhawat J, Jain R, Gaikwad S, Satav A, Purohit H, Triari G, Daganawala H. Laboratory investigations on the diagnosis of tuberculosis in the malnourished tribal population of meghat, India. PLoS One [Internet] 2013;8:e54652. Available from: NS -.
[28] Kerkhoff A, Wood R, Lowe D, Vogt M, Lawn S. Predictive value of a recombinant fusion protein polyprotein PstS1-LEP for tuberculosis diagnosis. J Immunoassay Immunochem [Internet] 2015;15:36-49. Available from: NS -.
[29] Kerkhoff A, Wood R, Lowe D, Vogt M, Lawn S. Predictive value of a recombinant fusion protein polyprotein PstS1-LEP for tuberculosis diagnosis. J Immunoassay Immunochem [Internet] 2015;15:36-49. Available from: NS -.
[30] Li J, Huang X, Chen H, Wang X, Zhu C, Zhao M, Song Q, Huang H, Xiao I, He H. Simultaneous detection of IgG and IgM antibodies to L-polymyxin B using a recombinant fusion protein polyprotein PstS1-LEP for tuberculosis diagnosis. Infect. Dis. (London, England) [Internet] 2015; 47: 643-649 Available from: NS -.
[31] Liu Q, Pan L, Han F, Luo B, He X, Xing A, et al. Proteomic profiling for plasma biomarkers of tuberculosis progression. Mol Med Rep [Internet] 2016;15:1501-9. Available from: NS -.
[32] Li Y, Zeng J, Shi J, Wang M, Rao M, Xue C, et al. A proteome-scale identification of novel antigenic proteins in Mycobacterium tuberculosis toward diagnostic and vaccine development. J Proteome Res [Internet] 2016;9:4812-22. Available from: NS -.
[33] Luo D, Wang L, Liu H, Li L, Liao Y, Yi X, et al. Ribokine screen from T7 phage displayed Mycobacterium tuberculosis genomic DNA library had good potential for the serodiagnosis of tuberculosis. Appl Microbiol Biotechnol [Internet] 2019;103: 5259-67. Available from: NS -.
Bai X, Yang Y, Liang J, An H, Wang J, Ling Y, et al. Diagnostic performance and
Meshram A, Agrawal U. Sandwich elisa for tubercular antigen detection in AFB
Mendes K, Malone M, Ndungu J, Suponitsky-Kroyter I, Cavett V, McEnaney P, et al.
Rosenkrands I, Aagaard C, Weldingh K, Brock I, Dziegiel MH, Singh M, et al.
Pope V, Sacksteder KA, Hererra JC, Gilman RH, Vargas-Prada S, Lopez Romero S,
Takenami I, de Oliveira CC, Lima FR, Soares J, Machado A, Riley LW, et al.
Van Beek S, Nhung N, Sy D, Sterk P, Tiemersma E, Cobelens F. Measurement of
Wang L, Deng X, Liu H, Zhao L, You X, Dai P, et al. The mimic epitopes of
Tiwari RP, Tiwari D, Garg SK, Chandra R, Bisen PS. Glycolipids of Mycobacterium
Wang Y, Lu B, Liu J, Xiao T, Wan K, Guan C. A multicenter clinical evaluation of
J.H. Wykowski et al.
8. Available from: NS - .
9. Available from: NS - .
10. Available from: NS - .
11. Available from: NS - .
12. Available from: NS - .
13. Available from: NS - .
14. Available from: NS - .
15. Available from: NS - .
16. Available from: NS - .
17. Available from: NS - .
18. Available from: NS - .
19. Available from: NS - .
20. Available from: NS - .
21. Available from: NS - .
22. Available from: NS - .
23. Available from: NS - .
24. Available from: NS - .
25. Available from: NS - .
26. Available from: NS - .
27. Available from: NS - .
28. Available from: NS - .
29. Available from: NS - .
30. Available from: NS - .
31. Available from: NS - .
32. Available from: NS - .
33. Available from: NS - .
34. Available from: NS - .
35. Available from: NS - .
36. Available from: NS - .
37. Available from: NS - .
38. Available from: NS - .
39. Available from: NS - .
40. Available from: NS - .
41. Available from: NS - .
42. Available from: NS - .
43. Available from: NS - .
44. Available from: NS - .
45. Available from: NS - .
46. Available from: NS - .
47. Available from: NS - .
48. Available from: NS - .
49. Available from: NS - .
50. Available from: NS - .
51. Available from: NS - .
52. Available from: NS - .
53. Available from: NS - .
54. Available from: NS - .
55. Available from: NS - .
56. Available from: NS - .
57. Available from: NS - .
58. Available from: NS - .
59. Available from: NS - .
60. Available from: NS - .
61. Available from: NS - .
62. Available from: NS - .
63. Available from: NS - .
64. Available from: NS - .
65. Available from: NS - .
66. Available from: NS - .
67. Available from: NS - .
68. Available from: NS - .
69. Available from: NS - .
70. Available from: NS - .
71. Available from: NS - .
72. Available from: NS - .
73. Available from: NS - .
74. Available from: NS - .
75. Available from: NS - .
76. Available from: NS - .
77. Available from: NS - .
78. Available from: NS - .
79. Available from: NS - .
80. Available from: NS - .
81. Available from: NS - .
82. Available from: NS - .
[85] Lima F, Santos AS, Oliveira RD, Silva CCR, Gonçalves CCM, Andrews JR, et al. Oral swab testing by Xpert® MTB/RIF Ultra for mass tuberculosis screening in prisons. *J. Clin. Tuberc. Other Mycobact. Dis.* [Internet] Elsevier 2020;19:100148. https://doi.org/10.1016/j.jctube.2020.100148.

[86] Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. *Lancet Infect Dis* 2021;21:354–65.

[87] Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, et al. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. *Lancet Glob. Heal.* 2021;9:e841–53.

[88] Zhu F, Ou Q, Zheng J, Zhou M, Chen H, Jiang X. Role of bronchoalveolar lavage fluid and serum interleukin-27 in the diagnosis of smear-negative pulmonary tuberculosis. *Medicine (Baltimore)* 2021;100(20):e25821.

[89] Arif S, Akhter M, Nahra A, Nisa Zu, Khan IH, Akhtar MW. Serodiagnostic evaluation of fusion proteins from multiple antigens of *Mycobacterium tuberculosis* for active TB. *Tuberculosis* Elsevier Ltd 2021;127:102053. https://doi.org/10.1016/j.tube.2021.102053.

[90] Bayaa R, Ndiaye MDB, Chedid C, Kokhreidze E, Tukvadze N, Banu S, et al. Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature for tuberculosis diagnosis and treatment monitoring. *Sci Rep* 2021;11:1–12.

[91] Han X, Li T, Fan Y, Wang X, Gu W, Lu W, et al. Screening of 20 *Mycobacterium tuberculosis* sRNAs in plasma for detection of active pulmonary tuberculosis. *Tuberculosis* [Internet] Elsevier Ltd 2021;129:102086. https://doi.org/10.1016/j.tube.2021.102086.

[92] Sodersten E, Ongarello S, Mantsoki A, Wyss R, Persing DH, Banderby S, et al. Diagnostic accuracy study of a novel blood-based assay for identification of tuberculosis in people living with HIV. *J Clin Microbiol* 2021;59(3). https://doi.org/10.1128/JCM.01643-20.

[93] Bitsen PS, Garg SK, Tiwari RP, Tagore PRN, Chandra R, Karnik R, et al. Analysis of the shotgun expression library of the *Mycobacterium tuberculosis* genome for immunodominant polypeptides: potential use in serodiagnosis. *Clin Diag Lab Immunol* [Internet] 2003;10(6):1051–8.

[94] Burbelo P, Keller J, Wagner J, Klimavicz J, Bayat A, Rhodes C, Diarra B, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Holland S, Browne S, Siddiqui S, Kovacs J. Serological diagnosis of pulmonary *Mycobacterium tuberculosis* infection by LIPS using a multiple antigen mixture. *BMC Microbiol.* [Internet] 2015; 15: 205Available from: NS -.